

# SIMRIS GROUP

## INTERIM REPORT

### JANUARY–MARCH 2025

#### QUARTER 1, JANUARY – MARCH 2025

- Net revenue decreased by 69 percent to SEK 159k (519k).
- EBITDA improved by 30 percent to SEK -3 724k (-5 325k).
- EBIT/ operating result improved by 19 percent to SEK -7 288k (-9 037k).

#### KEY EVENTS DURING THE QUARTER

- Simris Group held an extraordinary general meeting on 20 January 2025. The general meeting resolved to enter into loan agreements from board and management totaling €140 000.
- Simris Biologics announced that one of its refined microcystin (MC) payloads variants demonstrated in-vitro efficacy nearly comparable to a leading ADC for the treatment of HER2-positive breast cancer. These results demonstrated the potential for further improvement and will act as a benchmark for further studies designed to guide the development of second-generation MC variants with improved properties.

#### KEY EVENTS AFTER THE END OF THE QUARTER

- Simris Group has entered into a bridge loan facility of up to EUR 450 000, extended existing loan agreements of EUR 600 000 with investors, and proposed that the Annual General Meeting resolves to extend loan agreements of EUR 140 000 with management and board members.

#### THE PERIOD IN BRIEF

SEK thousands	Jan-Mar 2025	Jan-Mar 2024	Δ	Full year 2024
Net revenue	159	519	-69%	2 890
EBITDA	-3 724	-5 325	30%	-17 593
EBIT / Operating result	-7 288	-9 037	19%	-34 714
Result before tax	-6 795	-10 007	32%	-38 178
Cash flow from operating activities	-5 284	-5 437	3%	-18 016
Cash at the end of the period	2 998	185	1521%	1 946



## CEO UPDATE

As a Simris Group we entered 2025 with clarity, resilience, and an unwavering commitment to scientific excellence. Our vision is bold: to become a trusted provider of next-generation payloads for targeted cancer therapies, and to drive innovation where it matters most—at the intersection of nature, science, and human health.

Our journey is centered on our unique capability to produce proprietary payloads for antibody-drug conjugates (ADCs), with the goal of delivering more targeted and effective treatments for cancer patients around the world.

The first three months of 2025 have led to great progress in driving forward our plans to generate further in-vitro and in-vivo data for our most advanced novel next generation microcystins payloads. In the last three months, with the review of recent study data in collaboration with an independent pharma company, we have demonstrated in-vitro efficacy approaching that of Kadcyla (a commercial ADC targeting solid tumours) for one of our microcystin variants. This variant will serve as a benchmark for comprehensive in-vitro and in-vivo studies of the next generation of microcystin variants. Current efforts focus on enhancing safety for non-solid tumor treatments.

For ADCs using microcystin dimers, additional strategies are under development, including optimization of linker positioning, spacer design, and linker chemistries.

To continue to achieve our key scientific milestones, we have actively advanced multiple ADC payload candidates with optimized efficacy and improved safety profiles and have laid the groundwork to generate mouse data in a forthcoming study to be supported by a prominent CDMO.

Our established preclinical collaborations, including those with leading academic institutions in New Zealand have continued to deepen our scientific understanding of the potential of our unique payloads, but also confirmed the broader potential of our compounds beyond oncology, including in areas such as peptide-drug conjugates (PDCs) and healthy aging.

Our strong Global IP portfolio ensures we can defend our position in a highly competitive field and prepare for future commercialization efforts.

In our continued efforts to retain a lean and focused operating model, we have put our Hammenhög facility and equipment on the market for sale, as this asset has been deemed not fit-for-use for the production of cyanobacteria-derived compounds.

**Dr Alexis Roberts-McIntosh**

CEO Simris Group



## OVERVIEW

### NET REVENUE AND PROFIT

The sales for the quarter decreased by 69% and amounted to SEK 159k (519k).

The EBITDA result for the quarter improved by 30% to SEK -3 724k (-5 325k). The EBIT/ operating result for the quarter improved by 19% to SEK -7 288k (-9 037k).

The financial net in the income statement improved by SEK 1 101k during the quarter. This improvement was mainly driven by positive currency translation effects resulting from a stronger SEK/EUR exchange rate applied to liabilities denominated in EUR.

Of the total improvement, SEK 310k (-306k) related to unrealized foreign exchange gains from the revaluation of a contingent purchase consideration in EUR for the acquisition of Simris Biologics.

The total inventory value amounted to SEK 481k (1 097k) at the end of the year. All inventory accounted for at the end of the year is related to Simris Biologics.

### FIXED ASSETS

The total book value of the Group's fixed assets amounted to SEK 142 632k (167 411) at the end of the year. Intangible Assets at the end of the year were SEK 128 670k (147 696k). Tangible Assets at the end of the period were SEK 13 962k (19 715k).

The depreciation of fixed assets was made according to relevant accounting standards with SEK 3 564k (3 712k) during the quarter. Fixed assets are depreciated over 5–10 years for most fixtures and fittings, and over the remaining lifetime for patents (15 years for the patents and technology gained through the Cyano Biotech acquisition, now renamed to Simris Biologics), and up to 50 years for the buildings.

### LIQUIDITY AND FINANCING

Cash flow from operating activities improved by 3 percent to SEK -5 284k (-5 437k) during the quarter. Cash flow amounted to SEK 1 052k (-5 480k) for the quarter. At the end of the period, cash and cash equivalents amounted to SEK 2 998k (185k). The total liabilities at the end of the period amounted to SEK 147 721k (153 704k).

The deferred tax liability at the end of the quarter amounting to SEK 38 677k (44 683k) is not a payable debt as it is related to the purchase price allocation of Simris Biologics.

It is important to note that €8m of the long-term debt on the balance sheet is associated with the acquisition of Cyano Biotech (now Simris Biologics). This is the maximum earn-out remaining to be paid for the acquisition of the ADC platform. For this to become payable, Simris Biologics would have to first earn sales revenue of at least €80m from the ADC platform over the next 15 years. This revenue would be expected to be at a very high profit margin. Importantly, Simris Group has executed a back-to-back agreement with Simris Biologics whereby Simris Biologics will recompense Simris Group for the amount of this future earn-out payment.

On December 23, 2024, Simris Group AB (publ) secured a financing package to strengthen its working capital. The measures included a directed share issue of 277 074 328 B-shares at SEK 0.05 per share, raising approximately SEK 13.85 million before transaction costs. The company also repaid €1.15k (as an offset in the directed issue) in outstanding convertible debenture, entered into new convertible loan agreements totaling €600k with an option for the lender to increase by €900k, and additional convertible loans of €140k to management which were approved by the extraordinary general meeting on January 20, 2025.

The Brand Laboratories FZ (TBL) had previously provided the business with a loan facility of €778k. The facility maturity date is 31 December 2025, and interest is charged at 1.0% per month. Interest will be accumulated and will start to be paid out starting on July 1, 2025.

On the 15th of April 2025, Simris Group entered into a bridge loan agreement with Osiris International Trustees Limited, as Trustee of Mountain High Trust, for a loan facility of up to EUR 450 000. The loan may be drawn in tranches and carries a monthly interest rate of 1.0%. The maturity date is 16 April 2026, although Simris Group has the right to repay the loan early without penalty. The maturity date may be accelerated in the event of an equity issuance. As of the date of this interim report, no drawdowns have been made under the facility.

The Board of Directors wishes to inform stakeholders that the company's current cash reserves may not be sufficient to cover ongoing operations through the end of the calendar year. We recognize the gravity of this situation and are actively working on multiple fronts to secure the necessary funding to support the company's ongoing operations and future growth. Efforts are underway and explore various financing options, including debt refinancing, potential loans, new investment opportunities, and strategic partnerships. The Board remains committed to ensuring the long-term stability and success of the company and will continue to update stakeholders as progress is made.

## EQUITY

The Group's equity amounted to SEK -1 071k (17 312k) at the end of the quarter. The solidity was -0.7 percent, compared with 3.6 percent on December 31, 2024.

The total number of shares amounted to 504 764 755 B and the share capital amounted to SEK 5 047 647,55. Each share has a quota value amounting to 0.01 SEK.

The company has in December carried out a directed issue of a total of SEK 13 854k mainly through offsetting for early repayment of the convertible debt. The transaction increases the number of shares by 277 074 328 and was partially registered in February and fully registered in April. The number of shares after this transaction will be 625 144 898 and the share capital will be SEK 6 251 448,98.

## OPTION PROGRAM

At the end of the period, Simris Group had one outstanding Option program.

Series 2022/1 consists of 1 750 000 options and was issued to the CEO of the company, at that time, in May 2022. The options have a term of three years, and each option gives the right to subscription of 1.35 B shares at a subscription price of SEK 0.90 per share. Utilization of outstanding options corresponds to a dilution of the share capital by 0.68 percent.

## STAFF AND ORGANIZATION

The average number of full-time equivalents (FTEs) employed during the quarter amounted to 6 (9). At the end of the quarter, the Group had 6 FTEs excluding the CEO and the CFO that are contracted as consultants.

## PARENT COMPANY

Simis Group AB is the parent company. Net revenue for the Parent Company during the quarter amounted to SEK 0k (67k). EBIT/ operating result amounted to SEK -2 297k (-4 575k) for the quarter. The result before tax amounted to SEK -2 102k (-5 215k) for the quarter.

## TRANSACTIONS WITH RELATED PARTIES

At the extraordinary general meeting held on January 20, 2025, Simris Group AB (publ) resolved to enter into loan agreements totaling EUR 140 000 with related parties, including Frank Puccio (EUR 50 000), Royce CoLabs AB, a company controlled by Jonathan Royce (EUR 10 000), Magnus Högström (EUR 30 000), Arminnovate Ltd, a company controlled by Dr Alexis Roberts-McIntosh (EUR 20 000), and Christoffer Tell AB, a company controlled by Christoffer Tell (EUR 30 000). Due to conflicts of interest among board members, the agreements were submitted to the general meeting for approval in accordance with the Swedish Companies Act. The loans carry an interest rate of 1.0 percent per month and mature on December 31, 2025. The lenders have the right to convert the outstanding loan amounts, including accrued interest, into B-shares at a subscription price of SEK 0.05 per share, subject to adjustment in the event of a future capital raise.

In addition to normal Board work during the quarter, Board Directors performed consulting services for the company, of which Frank Puccio SEK 25k, Magnus Högström SEK 25k and Jonathan Royce SEK 23k.

## ACCOUNTING PRINCIPLES

Simris Group prepares its accounts in accordance with the Annual Accounts Act and the Accounting Boards general advice 2012:1(K3). Information on accounting principles in general is provided in the Financial Statement for 2024.

## AUDIT

This report has not been reviewed by Simris Group's auditor.

## RISKS AND UNCERTAINTIES

Simris Group's operations, financial position and earnings can be affected by a number of risks and uncertainties. These are described in Simris Group's Financial Statement for 2024, at [www.simrisgroup.com](http://www.simrisgroup.com).

Simris Group is in the start-up phase and still lacks sufficient earnings to cover the costs of the business through sales revenue. Simris Group is reliant upon planned additional external funding to be able to continue its operations, repay loans, and implement growth plans. Whilst the Board is confident that the business is in its strongest position ever, and that it will be able to raise the funds required for future investment and growth, there is always a risk that capital markets change and that new capital cannot be accessed when needed, or that new capital cannot be obtained on satisfactory terms, or that the procured capital is insufficient to finance the planned operations in accordance forecasts and objectives.

**14 May 2025**

The Board of Directors and the CEO confirm that this report provides a fair overview of the Group's operations, position and results.

**Jonathan Royce**  
Chairman

**Magnus Högström**  
Board Director

**Frank Puccio**  
Board Director

**Dr Alexis Roberts-McIntosh**  
CEO



## INCOME STATEMENT - CONSOLIDATED GROUP

SEK thousands	Jan-Mar 2025	Jan-Mar 2024	Full year 2024
Net revenue	159	519	2 890
Change of finished goods and work in progress	0	-17	-404
Other operating income	0	0	263
Raw materials and consumables	-80	-179	-1 269
Other external expenses	-2 470	-3 193	-11 639
Personnel expenses	-1 333	-2 455	-7 434
Depreciation and amortization	-3 564	-3 712	-17 121
<b>Operating result / EBIT</b>	<b>-7 288</b>	<b>-9 037</b>	<b>-34 714</b>
Financial net	493	-970	-3 464
<b>Result before tax</b>	<b>-6 795</b>	<b>-10 007</b>	<b>-38 178</b>
Tax	801	862	3 573
<b>Result for the period</b>	<b>-5 994</b>	<b>-9 145</b>	<b>-34 605</b>
(Attributable to the parent company's shareholders)	-5 994	-9 145	-34 605

## BALANCE SHEET - CONSOLIDATED GROUP

SEK thousands	31 Mar 2025	31 Mar 2024	31 Dec 2024
<b>Assets</b>			
<b>Fixed Assets</b>			
Intangible assets	128 670	147 696	138 974
Tangible assets	13 962	19 715	15 029
<b>Total Fixed Assets</b>	<b>142 632</b>	<b>167 411</b>	<b>154 003</b>
<b>Current Assets</b>			
Inventory	481	1 097	509
Other receivables	539	2 323	599
Cash and bank balances	2 998	185	1 946
<b>Total Current Assets</b>	<b>4 018</b>	<b>3 605</b>	<b>3 054</b>
<b>Total Assets</b>	<b>146 650</b>	<b>171 016</b>	<b>157 057</b>
<b>Equity and Liabilities</b>			
Equity	-1 071	17 312	5 641
<b>Provisions</b>			
Deferred tax	38 677	44 683	41 816
<b>Liabilities</b>			
Long-term Liabilities	88 471	94 137	93 631
Short-term Liabilities	20 573	14 884	15 969
<b>Total Liabilities</b>	<b>147 721</b>	<b>153 704</b>	<b>151 416</b>
<b>Total Equity and Liabilities</b>	<b>146 650</b>	<b>171 016</b>	<b>157 057</b>

## CASH FLOW ANALYSIS - CONSOLIDATED GROUP

SEK thousands	Jan-Mar 2025	Jan-Mar 2024	Full year 2024
Cash flow from operating activities before changes in working capital	-3 575	-6 111	-22 088
Cash flow from working capital	-1 709	674	4 072
<b>Cash flow from operating activities</b>	<b>-5 284</b>	<b>-5 437</b>	<b>-18 016</b>
Cash flow from investing activities	0	0	-613
Cash flow from financing activities	6 336	-43	14 910
<b>Cash flow for the period</b>	<b>1 052</b>	<b>-5 480</b>	<b>-3 719</b>
Cash and cash equivalents opening balance	1 946	5 665	5 665
<b>Cash and cash equivalents closing balance</b>	<b>2 998</b>	<b>185</b>	<b>1 946</b>

## CHANGES IN EQUITY - CONSOLIDATED GROUP

SEK thousands	Jan-Mar 2025	Jan-Mar 2024	Full year 2024
Opening balance	5 641	25 614	25 614
Issue	0	0	13 854
Issue costs	0	0	0
Translation differences	-718	843	778
Result for the period	-5 994	-9 145	-34 605
<b>Closing balance</b>	<b>-1 071</b>	<b>17 312</b>	<b>5 641</b>

## KEY FIGURES - CONSOLIDATED GROUP

	Jan-Mar 2025	Jan-Mar 2024	Full year 2024
Net revenue (kSEK)	159	519	2 890
EBIT (kSEK)	-7 288	-9 037	-34 714
Cash at the end of the period (kSEK)	2 998	185	1 946
Equity (kSEK)	-1 071	17 312	5 641
Earnings per share (SEK)	neg.	neg.	neg.
Earnings per share after full dilution (SEK)	neg.	neg.	neg.
Equity per share (SEK)	-0,002	0,05	0,02
Equity per share after full dilution(SEK)	-0,002	0,05	0,02
Number of shares, average	417 712 430	348 070 570	348 070 570
Number of shares, end of period	504 764 755	348 070 570	348 070 570
Number of shares after full dilution*	504 764 755	348 070 570	348 070 570
Solidity (%)	-0.7	10.1	3.6
Balance sheet total (kSEK)	146 650	171 016	157 057
Cash liquidity (%)	17	17	16
Average number of employees	6	9	7

\*Simris Group has one outstanding warrant program. Dilution effects have not been taken into account for any of the programs for any of the above period, as the average price of Simris Groups's share in each period has been less than the subscription price in the program. If full subscription takes place within the framework of the option program, the number of shares will increase by 2 362 500.



## INCOME STATEMENT - PARENT COMPANY

SEK thousands	Jan-Mar 2025	Jan-Mar 2024	Full year 2024
Net revenue	0	67	159
Change of finished goods and work in progress	0	-17	-202
Other operating income	0	0	255
Raw materials and consumables	0	-22	-249
Other external expenses	-1 451	-2 408	-8 772
Personnel expenses	-100	-1 449	-2 761
Depreciation and amortization	-746	-746	-5 186
<b>Operating result / EBIT</b>	<b>-2 297</b>	<b>-4 575</b>	<b>-16 756</b>
Financial net	195	-640	-3 096
<b>Result before tax</b>	<b>-2 102</b>	<b>-5 215</b>	<b>-19 852</b>
Tax	0	-3	114
<b>Result for the period</b>	<b>-2 102</b>	<b>-5 218</b>	<b>-19 738</b>

## BALANCE SHEET - PARENT COMPANY

SEK thousands	31 Mar 2025	31 Mar 2024	31 Dec 2024
<b>Assets</b>			
<b>Fixed Assets</b>			
Tangible assets	12 200	17 386	12 947
Financial assets	129 046	127 317	132 478
<b>Total Fixed Assets</b>	<b>141 246</b>	<b>144 703</b>	<b>145 425</b>
<b>Current Assets</b>			
Inventory	0	382	0
Other receivables	367	1 435	433
Cash and bank balances	2 461	0	909
<b>Total Current Assets</b>	<b>2 828</b>	<b>1 817</b>	<b>1 342</b>
<b>Total Assets</b>	<b>144 074</b>	<b>146 520</b>	<b>146 767</b>
<b>Equity and Liabilities</b>			
<b>Equity</b>	<b>36 099</b>	<b>38 868</b>	<b>38 201</b>
<b>Provisions</b>			
Deferred tax	0	117	0
<b>Liabilities</b>			
Long-term Liabilities	88 471	94 137	93 631
Short-term Liabilities	19 504	13 398	14 935
<b>Total Liabilities</b>	<b>107 975</b>	<b>107 652</b>	<b>108 566</b>
<b>Total Equity and Liabilities</b>	<b>144 074</b>	<b>146 520</b>	<b>146 767</b>



## ABOUT SIMRIS GROUP

Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics. Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

## FINANCIAL CALENDAR:

Annual General Meeting	28 May 2025
Interim Report Q2, 2025	13 Aug 2025
Interim Report Q3, 2025	12 November 2025
Year-end Report 2025	25 February 2026

## Certified Adviser

Amudova AB is the Company's Certified Adviser on Nasdaq First North and can be reached at [info@amudova.se](mailto:info@amudova.se) or +46 (0) 8-546 017 58.

## FOR MORE INFORMATION:

Dr Alexis Roberts-McIntosh, CEO

Phone: +44 (0)7940 585298

Email: [IR@simris.com](mailto:IR@simris.com)

## KEY FIGURE DEFINITIONS

**Balance sheet total** - The sum of all assets in the balance sheet or sum of all liabilities and equity.

**Equity per share** - Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number of shares at the end of the period.

**Equity per share after full dilution** - Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number shares at the end of the period taking into account after conversion and adjusted for effect of share-based payments.

**Cash liquidity** - Current assets excluding inventories and work in progress as a percentage of current liabilities

**Net revenue** - Operating main income, invoiced costs, side income and income corrections.

**Earnings per share** - Earnings for the period divided by the number of shares after the end of the period.

**Earnings per share after full dilution** - Earnings for the period divided by number shares after the end of the period, taking into account after conversion and adjusted for effect of share-based payments.

**EBIT/ Operating result** - Result before financial expenses and tax.

**Solidity** - Adjusted equity at the end of the period as a percentage of total asset.

*This information is information that Simris Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on 14 May 2025.*

